

Supplementary Table 2. Clinical characteristics of patients from Severance Hospital according to COVID-19 vaccination history before biopsy

Characteristic	Vaccination before kidney biopsy (n = 83)	No vaccination before kidney biopsy (n = 24)	p-value
Age (yr)	45.0 (34.5–58.0)	41.0 (33.0–54.5)	0.52
Female sex	43 (51.8)	17 (70.8)	0.16
Days from first vaccination to kidney biopsy ^b	140.0 (77.0–272.0)	-	-
Vaccine regimen (first)			-
BNT162b2 (Pfizer/BioNTech)	45 (54.2)	-	
ChAdOx1 nCoV-19 (Oxford/AstraZeneca)	16 (19.3)	-	
Ad26.COV.S (Johnson & Johnson)	10 (12.0)	-	
mRNA-1273 (Moderna Biotech)	6 (7.2)	-	
Unknown regimen	5 (6.0)	-	
NVX-CoV2373 (Novavax)	1 (1.2)	-	
Pathologic diagnosis			0.67
Acute interstitial nephritis	2 (2.4)	0 (0)	
Chronic tubulointerstitial nephritis	1 (1.2)	0 (0)	
Focal segmental glomerulosclerosis	11 (13.3)	4 (16.7)	
Glomerular basement membrane abnormality	2 (2.4)	0 (0)	
Hypertensive	1 (1.2)	0 (0)	
IC-GN	2 (2.4)	1 (4.2)	
IgAN/Henoch-Schönlein purpura nephritis	44 (53.0)	13 (54.2)	
Lupus nephritis	4 (4.8)	0 (0)	
Lymphoma	0 (0)	1 (4.2)	
Membranoproliferative glomerulonephritis	1 (1.2)	1 (4.2)	
Membranous nephropathy	5 (6.0)	3 (12.5)	
Minimal change disease	1 (1.2)	1 (4.2)	
Nonspecific histology	2 (2.4)	0 (0)	
Pauci-immune glomerulonephritis	4 (4.8)	0 (0)	
Podocytopathy	2 (2.4)	0 (0)	
Thrombotic microangiopathy	1 (1.2)	0 (0)	

Data are expressed as median (interquartile range) or number (%).

COVID-19, coronavirus disease 2019; IgAN, immunoglobulin A nephropathy; IC-GN, immune complex-mediated glomerulonephritis.

^aPatients with a history of COVID-19 before biopsy were excluded; ^bmissing values in 66 (79.5%).